Do Patients Benefit from Autotransplants for Advanced Ovarian Cancer?-Reference-Cited by-同舟云学术

Do Patients Benefit from Autotransplants for Advanced Ovarian Cancer?

Published:2000 Issue: Volume: Page:177-189
ISSN:
Container-title:Current Controversies in Bone Marrow Transplantation
language:
Short-container-title:

Author:

Ruzich Janet,Stiff Patrick J.

Publisher

Humana Press

Link

http://link.springer.com/content/pdf/10.1007/978-1-59259-657-7_13.pdf

Reference68 articles.

1. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer, N. Engl. J. Med., 335 (1996) 1950–1955.

2. Markman M, Bundy B, Benda J, et al. Randomized phase III study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal OP) CIS in optimal residual ovarian cancer (OC): an intergroup trial (GOG, SWOG, ECOG), Proc. Am. Soc. Clin. Oncol.,17 (1998) 361a(Abstract).

3. Landis SH, Murray T, Bolden S, and Wingo PA. Cancer statistics, 1998 [published errata appear in CA Cancer J. Clin., 48 (1998) 192 and 48 (1998) 329], CA Cancer J. Clin., 48 (1998) 6–29.

4. Herben VIVI, Panday VR, Richel DJ, et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer, J. Clin. Oncol., 17 (1999) 747–755.

5. Kohn EC, Sarosy GA, et al. A Phase I/11 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer, Gynecol. Oncol.,(1996) 181–191(Abstract).